| Record ID | marc_columbia/Columbia-extract-20221130-014.mrc:64228560:2030 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-014.mrc:64228560:2030?format=raw |
LEADER: 02030cam a2200457 a 4500
001 6775736
005 20080721143133.0
007 cr cn|||||||||
008 061026s2006 dcua b f000 0 eng
010 $a 2006475797
035 $a(OCoLC)ocm78843434
040 $aDLC$cDLC$dVVK$dAFQ$dNLM$dBTCTA
016 7 $a101299060$2DNLM
029 1 $aNLM$b101299060
035 $a(OCoLC)78843434
042 $apcc
043 $an-us---
050 00 $aRM301.25$b.A888 2006
060 00 $a2007 B-520
060 10 $aQV 736$bA935r 2006
082 00 $a615/.1072$222
049 $aZCUA
100 1 $aAustin, David H.
245 10 $aResearch and development in the pharmaceutical industry /$cCongress of the United States, Congressional Budget Office .
260 $aWashington, D.C. :$bCongress of the United States, Congressional Budget Office,$c2006.
300 $avii, 55 p. :$bill. ;$c28 cm.
440 0 $aCBO study
500 $a"David H. Austin prepared this report ... "-- Pref.
504 $aIncludes bibliographical references (p. [51]-55).
500 $a"October 2006."
505 0 $aIntroduction and summary -- Trends in R&D spending and output of new drugs -- What does lit cost to develop new drug? -- Does federal R&D spending stimulate or substitute for private-sector spending? -- Has the drug industry's innovative performance declined? -- Profitability and R&D investment in the drug industry -- References -- Tables -- Figures -- Boxes.
530 $aAlso available via the World Wide Web.
538 $aSystem requirements: Adobe Acrobat Reader.
650 0 $aDrugs$xResearch$xGovernment policy$zUnited States.
650 0 $aDrug development$zUnited States.
650 0 $aPharmaceutical industry$xEconomic aspects.
650 12 $aDrug Industry$xtrends$zUnited States.
650 22 $aResearch$xeconomics$zUnited States.
710 1 $aUnited States.$bCongressional Budget Office.
856 41 $uhttp://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf$zFull Report Online
852 30 $boff,docs$hY 10.2:P 49